

REVIEW

Cardiac Resynchronization Therapy in Heart Failure: Patients with Narrow QRS

Hector Anninos, MD, Spyridon Koulouris MD, FESC

**First Department of Cardiology, Evagelismos
General Hospital of Athens, Athens, Greece**

Heart failure remains a significant health problem in the Western countries despite the evolution achieved in terms of heart disease prevention and medical treatment. Its incidence and its prevalence reach 550,000/year and 5 million respectively in the United States. As a consequence, heart failure causes about 287,000 deaths in the US each year and puts a financial burden to the health system of \$29.6 billion dollars due to the increasing number of hospitalizations especially in elderly patients.^{1,2}

Cardiac resynchronization therapy (CRT) is a relatively recent advance in the management of heart failure patients, which has been very hopeful since its development. Large trials have established the efficacy of CRT in improving functional capacity (MUSTIC, MIRACLE) and reducing mortality (COMPANION, CARE HF) in patients with advanced heart failure (NYHA III-IV), reduced ejection fraction (EF<35%) and wide QRS complex >120 - 130 ms (MIRACLE)³⁻⁷. Data from meta-analyses also confirm the beneficial effect of CRT with respect to mortality from worsening heart failure and all cause mortality in patients with *wide QRS complex*.⁸⁻¹⁰

Nevertheless, not all patients suffering from heart failure have a prolonged QRS. On the contrary, it has been reported that nearly 50% of heart failure patients have a QRS < 120 ms.¹¹ Moreover, CRT has been shown to improve haemodynamic variables in patients with heart failure and narrow QRS.¹² Achilli et al,¹³ who studied 52 patients, reported that CRT produced similar clinical and functional benefit in patients with wide or narrow QRS, the cut-off point being 120 ms provided they had mechanical dyssynchrony. Bleeker et al¹⁴ came up with similar results when they compared 33 patients with normal QRS duration with an equal number of subjects with wide QRS. All participants ought to have mechanical dyssynchrony >65 ms on tissue Doppler imaging (TDI) study. Yu et al¹⁵ confirmed these findings, showing evidence of reverse remodelling and clinical improvement in 102 patients with heart failure. Half of them demonstrated a normal width of the QRS complex and had baseline systolic dyssynchrony. Gasparini et al.¹⁶ evaluated a total number of 376 patients with impaired systolic function and concluded that CRT was beneficial in terms of both clinical parameters and left ventricular (LV) geometry in a long-term basis, regardless of the QRS duration.

Notably, the patients with a narrow QRS were not selected on the basis of mechanical dyssynchrony, but they constituted only a small percentage of the whole study population (46/376 or 12%). Another meta-analysis by Jeevanantham et al.¹⁷ incorporating data from the studies by Yu, Bleeker and Achilli, where the patients with narrow QRS were selected on the basis of mechanical dyssynchrony, showed that there was a significant improvement in mean LVEF and six minutes walk distance (6 MWD) at the end of a follow-up period exceeding 3 months. When results from other studies with longer follow up period were included, the improvement in the former indices was even more impressive.

The ESTEEM-CRT study on the other hand, showed that patients with narrow QRS and mechanical dyssynchrony (Ts-SD-12 echocardiographic variable) did not benefit from CRT with regard to exercise tolerance and reverse remodelling.¹⁸ Moreover, a recent study enrolling 90 patients with mechanical asynchrony regardless of their QRS width, did not find significant difference in the outcome (reduction of LVESV by 15% or more) between those with wide or narrow QRS after CRT implantation, at the end of the follow up period (1±2 months), although there was a trend for better outcome in the wide QRS arm (53 vs. 73% p=0.084).¹⁹

All these results however, emerge from relatively small, non-randomized studies. Subgroup analyses from larger, randomized trials may provide more reliable information. In the CARE -HF trial, those with QRS less than 160 ms did not benefit from CRT.⁷ The MADIT-CRT trial which evaluated the effect of CRT-D over mere ICD implantation in patients with mild heart failure in a randomized manner, showed that resynchronization was effective in preventing new heart failure events in patients with a baseline QRS of more than 150 ms.²⁰ Similar results were obtained from the REVERSE trial. In this study 610 patients with NYHA class I/II heart failure, QRS duration >120 ms, LV end-diastolic dimension >55 mm, and LVEF <40% were randomized to active therapy (CRT on) or control (CRT off) for 12 months. A significant reduction in LV end-diastolic and end-systolic volume indexes and an increase in LVEF at 12 months was reported, although only for those with a baseline QRS > 140 ms.²¹

The first randomized attempt to assess the issue of CRT in narrow QRS was the RethinQ study. A total of 172 patients with a standard indication for an ICD and QRS<130 ms, were randomly assigned to receive or not a CRT device and were followed up for 6 months. In the prespecified group of resynchronised patients with normal QRS duration the primary end point of increase in O₂ consumption by at least 1.0 ml per kg of body weight per minute during cardiopulmonary exercise was not achieved, in contrast to the rest of the participants who received CRT and had a QRS wider than 120 ms.²²

In conclusion, the concept of CRT efficacy in heart failure patients with narrow QRS is still under evaluation. The initial relatively small non-randomized trials have yielded encouraging results. However, data from larger randomized studies challenge these favourable conclusions and the RethinQ trial, the first to address this particular issue in a randomized fashion, failed to confirm the usefulness of CRT in this setting. Nevertheless, more data from large randomized trials are still needed to further elucidate this matter. A new study aiming at evaluating the effects of CRT on mortality and morbidity of subjects with heart failure due to LV systolic dysfunction, already receiving optimized medical therapy, with a narrow QRS width (< 130 ms) and echocardiographic evidence of ventricular dyssynchrony (EchoCRT) is currently recruiting patients.²³ Interesting results that will probably enlighten the field are anticipated due to the specific design and the hard endpoints of this trial.

REFERENCES

1. http://www.cdc.gov/dhdsplibrary/pdfs/fs_heart_failure.pdf
2. American Heart Association. Heart Disease and Stroke Facts, 2006 Update. Dallas, Texas: AHA, 2006.
3. Cazeau S, Leclercq C, Lavergne T et al. Effects of multisite Biventricular pacing in patients with heart failure and intraventricular conduction delay. *N Engl J Med* 2001; 344: 873–880.
4. Leclercq C, Walker S, Linde C et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation. *Eur Heart J* 2002; 23: 1780–1787.
5. Abraham WT, Fisher WG, Smith AL et al. Cardiac resynchronization in chronic heart failure. *N Engl J Med* 2002; 346: 1845–1853.
6. Bristow MR, Saxon LA, Boehmer J et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. *N Engl J Med* 2004; 350: 2140–2150.
7. Cleland JGF, Daubert JC, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med* 2005; 352: 1539–1549.
8. Bradley DJ, Bradley EA, Baughman KL et al. Cardiac resynchronization and death from progressive heart failure: a meta-analysis of randomized controlled trials. *JAMA* 2003; 289: 730–740.
9. Rivero-Ayerza M, Theuns DA, Garcia-Garcia HM, Boersma E, Simoons M, Jordaens LJ. Effects of cardiac resynchronization therapy on overall mortality and mode of death: a meta-analysis of randomized controlled trials. *Eur Heart J* 2006; 2: 2682–2688.
10. McAlister FA, Ezekowitz JA, Wiebe N et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. *Ann Intern Med* 2004; 141: 381–390.
11. Yu CM, Lin H, Zhang Q, Sanderson JE. High prevalence of LV systolic and diastolic asynchrony in patients with congestive heart failure and normal QRS duration. *Heart* 2003; 89: 54–60.
12. Turner MS, Bleasdale RA, Mumford CE, Frenneaux MP, Morris-Thurgood JA. LV pacing improves haemodynamic variables in patients with heart failure with a normal QRS duration. *Heart* 2004; 90: 502–505.
13. Achilli A, Sassara M, Ficili S et al. Long-term effectiveness of cardiac resynchronization therapy in patients with refractory heart failure and “narrow” QRS. *J Am Coll Cardiol* 2003; 42: 2117–2124.
14. Bleeker GB, Holman ER, Steendijk P et al. Cardiac resynchronization therapy in patients with a narrow QRS complex. *J Am Coll Cardiol* 2006; 48: 2243–2250.
15. Yu CM, Chan YS, Zhang Q et al. Benefits of cardiac resynchronization therapy for heart failure patients with narrow QRS complexes and coexisting systolic asynchrony by echocardiography. *J Am Coll Cardiol* 2006; 48: 2251–2257.
16. Gasparini M, Regoli F, Galimberti P et al. Three years of cardiac resynchronization therapy: Could superior benefits be obtained in patients with heart failure and narrow QRS? *Pacing Clin Electrophysiol* 2007; 30 (Suppl. 1): S34–S39.
17. Vinodh Jeevanantham, Wojciech Zaręba, Sankar Navaneethan et al. Metaanalysis on effects of cardiac resynchronization therapy in heart failure patients with narrow QRS complex. *Cardiology J* 2008;15: 230–236
18. Donahue T, Niazi I, Leon A, et al. ESTEEM-CRT Investigators One Year Follow-Up of CRT in Narrow QRS Patients with Mechanical Dyssynchrony: ESTEEM-CRT. *Circulation* 2008;118:S949
19. Rafique A, Peter T, Naqvi T. A revised approach to patient selection for cardiac resynchronization treatment using multiple asynchrony parameters in Narrow and Wide-QRS cardiomyopathy causes cardiac reverse remodelling: a single center non-randomized prospective study. *Europace* 2010;12: 1127–1135.
20. Moss A, Hall J, Cannom D et al. for the MADIT-CRT Trial Investigators. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events. *N Engl J Med* 2009;361:1329-38.
21. Sutton M, Ghio S, Plappert T et al on Behalf of the REsynchronization reverses Remodeling in Systolic left Ventricular dysfunction (REVERSE) Study Group. Cardiac Resynchronization Induces Major Structural and Functional Reverse Remodeling in Patients With New York Heart Association Class I/II Heart Failure. *Circulation* 2009;120:1858-1865.
22. Beshai J, Grimm R, Nagueh S, et al, for the RethinQ Study Investigators. Cardiac-Resynchronization Therapy in Heart Failure with Narrow QRS Complexes *N Engl J Med* 2007;357:2461-71.
23. ClinicalTrials.gov Identifier: NCT00683696